Erastin

For research use only. Not for use in humans.

目录号:S7242

Erastin Chemical Structure

CAS No. 571203-78-6

Erastin是一种ferroptosis激活剂,通过作用于线粒体VDAC而起作用,选择性作用于携带致癌基因RAS的肿瘤细胞。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2449.7 现货
RMB 647.26 现货
RMB 1199.29 现货
RMB 6303.21 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Erastin发表文献99篇:

产品安全说明书

Ferroptosis抑制剂选择性比较

生物活性

产品描述 Erastin是一种ferroptosis激活剂,通过作用于线粒体VDAC而起作用,选择性作用于携带致癌基因RAS的肿瘤细胞。
靶点
Ferroptosis [1]
体外研究

Erastin选择性致死致癌的Ras突变体细胞系,并触发独特的fe依赖性的称为ferroptosis的非凋亡细胞死亡。[1] [2] Erastin直接结合VDAC2并且使得通过NADH-依赖方式产生ROS导致线粒体损害,在一些表达激活突变的肿瘤细胞中,通过RAS-RAF-MEK途径诱导细胞死亡。[3] 此外,erastin通过诱导ROS介导的CID(胱天蛋白酶非依赖性细胞死亡),强烈增强了野生型EGFR细胞的作用。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human BJeH cells MmLXSpVv[3Srb36gZZN{[Xl? NVfueVJJPiCq M2\qVmlv\HWldHnvckBw\iC{ZXHjeIl3\SCxeInn[Y4he3CnY3nld{Bxem:mdXP0bY9vKGmwIHj1cYFvKEKMZVigZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgVmFUKGGodHXyJFYhcHK|IHL5JGRETi2kYYPl[EBndG:5IHP5eI9u\XS{aXOgZY5idHm|aYO= M{nWT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOyN|IyLz5{MkizNlMzOTxxYU6=
human BJeLR cells NHvNWZZEgXSxdH;4bYPDqGG|c3H5 MnPENVAh|ryP NV\3U4gyOTJiaB?= NFLZN4dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDUmWOUjDj[YxteyCneIDy[ZN{cW6pIGLBV{BIOTKYIH31eIFvfCCjdDCxNEB2VSCjdDCxNkBpenNiYomgeJJ6eGGwIHLseYUhe3SjaX7pcoc> MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNlEoRjJ{OEOyN|IyRC:jPh?=
human BJ cells MoDiSpVv[3Srb36gZZN{[Xl? M2H3R|QvPiEQvF2= M3nqRmlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgc5hq\GG2aY\lJJNx\WOrZYOgbY4hcHWvYX6gRmoh[2WubIOg[ZhxemW|c3nu[{BVTVKWLDDMWEwhW1RiYX7kJHJCWyCJMULWJI12fGGwdDDn[Y5meyClZXzsd{BifCB2Lk[geW0> NHPDUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human BJ cells MlfFSpVv[3Srb36gZZN{[Xl? MWO5JO69VQ>? NFfndJlKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDCTkBk\WyuczDlfJBz\XO|aX7nJHRGWlRuIFzUMEBUXCCjbnSgVmFUKEdzMm[gcZV1[W62IHflcoV{KGOnbHzzJIF1KDlidV2u MoThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human BJ cells MWPGeY5kfGmxbjDhd5NigQ>? NV24eHpDUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRmoh[2WubIOg[ZhxemW|c3nu[{BVTVKWLDDMWEwhW1RiYX7kJHJCWyCJMULWJI12fGGwdDDn[Y5meyCrbjDwdoV{\W6lZTDv[kBWODF{NjDifUB1enmyYX6gZox2\SCneHPseZNqd25ibXX0bI9lNCCLQ{WwQVMyNjJizszNMi=> M4exRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human A673 cells MWjGeY5kfGmxbjDhd5NigQ>? NYnIZ25xUW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gRVY4OyClZXzsd{whTUN3ME2zNEDPxE1w NFHtTos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human MX2 cells M{fTe2Z2dmO2aX;uJIF{e2G7 Ml\qTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iTWiyJINmdGy|LDDFR|UxRTF6IN88UU4> Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human HOS cells NVTub4tlTnWwY4Tpc44h[XO|YYm= NVv5V4l4UW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gTG9UKGOnbHzzJEwhTUN3ME2xO{DPxE1w MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human Hs925.T cells NELOVGRHfW6ldHnvckBie3OjeR?= MVrJcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCKc{myOU5VKGOnbHzzMEBGSzVyPUG3JO69VS5? NWPQN2FqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human Hs51.T cells M{LDO2Z2dmO2aX;uJIF{e2G7 NEDDSHVKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDId|UyNlRiY3XscJMtKEWFNUC9NVIh|ryPLh?= NVPVWmpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human EWS502 cells M4S1WGZ2dmO2aX;uJIF{e2G7 M2PNcGlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFXXV|UxOiClZXzsd{whTUN3ME2xNEDPxE1w MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human BJ cells MY\GeY5kfGmxbjDhd5NigQ>? NGTkSG5KdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBVTVKWIHX4dJJme3OrbnegbJVu[W5iQlqgZ4VtdHNuIFXDOVA:OTBizszNMi=> NILDc4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human TC71 cells MknzSpVv[3Srb36gZZN{[Xl? M4f3bWlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIGTDO|Eh[2WubIOsJGVEPTB;MUCg{txONg>? Mk\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human U937 cells MVvGeY5kfGmxbjDhd5NigQ>? NGnnbFFKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDVPVM4KGOnbHzzMEBGSzVyPUGwJO69VS5? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human SK-N-MC cells NWHlRYhXTnWwY4Tpc44h[XO|YYm= M4L6dWlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIGPLMW4uVUNiY3XscJMtKEWFNUC9NVAh|ryPLh?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human TC32 cells M4nIZmZ2dmO2aX;uJIF{e2G7 MmLNTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iVFOzNkBk\Wyucx?= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human U2OS cells NEHXNo1HfW6ldHnvckBie3OjeR?= NI\zRZVKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDVNm9UKGOnbHzzMEBGSzVyPU[g{txONg>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human LNCaP cells NHywXHdHfW6ldHnvckBie3OjeR?= MV;JcoR2[3Srb36gc4Yh[2WubDDk[YF1cCCrbjDoeY1idiCOTlPhVEBk\WyuczygSWM2OD14IN88UU4> NX\yOFhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1Olg4PDhpPkG3OVY5PzR6PD;hQi=>
human Calu1 cells NWr4SJBVTnWwY4Tpc44h[XO|YYm= MnywTY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3MTDj[YxteyCneIDy[ZN{cW6pIFvSRXMhf2m2aDDhZ5RqfmG2aX7nJI12fGG2aX;ud{BjgSC2conwZY4h[my3ZTDlfINtfXOrb36gZZN{[XluIFnDOVA:PCEQvF2u M4P3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NU[4O|Q5Lz5zN{W2PFc1QDxxYU6=
human SKUT cells MUTGeY5kfGmxbjDhd5NigQ>? MofrTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iU1vVWEBk\WyuczygSWM2OD12IN88UU4> MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human MES-SA cells MYHGeY5kfGmxbjDhd5NigQ>? MoDFTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iTVXTMXNCKGOnbHzzMEBGSzVyPUOg{txONg>? MmDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human SVR cells NETW[5NHfW6ldHnvckBie3OjeR?= NXfSfHd2UW6mdXP0bY9vKG:oIHPlcIwh\GWjdHigbY4hcHWvYX6gV3ZTKGOnbHzzMEBGSzVyPUKuOUDPxE1w MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human HT1080 cells MkK0SpVv[3Srb36gZZN{[Xl? M4\IRmlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFjUNVA5OCClZXzsd{BqdiCycnXz[Y5k\SCxZjDQSE06QDB3OTDifUB1enmyYX6gZox2\SCneHPseZNqd25ibXX0bI9lNCCLQ{WwQVEh|ryPLh?= NEfPUoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W2PFc1QCd-MUe1Olg4PDh:L3G+
human BJ cells M{i2T2Z2dmO2aX;uJIF{e2G7 M3fzcmlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFLKJINmdGy|IHX4dJJme3OrbnegWGVTXCxiTGSsJHNVKGGwZDDSRXMhTzF{VjDteZRidnRiZ3Xu[ZMh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiUFStPVgxPTliYomgeJJ6eGGwIHLseYUh\XilbIXzbY9vKG2ndHjv[EwhUUN3ME2wMlkh|ryPLh?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV4OEe0PEc,OTd3Nki3OFg9N2F-
human HeLa cells MXTGeY5kfGmxbjDhd5NigQ>? M2DrPGlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFjlUIEh[2WubIOsJGVEPTB;MD62JO69VS5? MkD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd3Nki3OFgoRjF5NU[4O|Q5RC:jPh?=
human CCF-STTG1 cells NHjnblVHfW6ldHnvckBie3OjeR?= NHq3UJhKdmirYnn0bY9vKG:oIGjjeEBqdiCqdX3hckBES0ZvU2TUS|Eh[2WubIOgZZN{\XO|ZXSgZZMh\2y3dHHtZZRmKHKnbHXhd4Uh[W[2ZYKgNkBpenNiYomg[ox2d3KxbXX0dpktKEmFNUC9NE4zKM7:TT6= NHrvZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE2Pid-Mk[yN|EyPTZ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
GPX4 / cleaved-PARP / cleaved-caspase3 / LC3 / p62 / LDH / HMGB1; 

PubMed: 27308510     


HL-60 and Jurkat cells were treated with erastin (5 μM) for 24 h and subjected to western blot analysis of the indicated proteins in whole cell extracts or supernatant. 

TfR1 / p-JNK / JNK / p-P38; 

PubMed: 31105999     


HL-60/NRAS (Q61L) cells were treated with erastin (5 μM) combined with SP600125 (10 μM) and SB202190 (10 μM) for 48 h. TfR1 expression and the phosphorylation of p38 (p-P38) and JNK1/2 (p-JNK1/2) were assayed by western blot. 

HSPA5 / p-EIF2AK3; 

PubMed: 28130223     


Western blot analysis indicated protein expression in PDAC cells following treatment with erastin (2.5-40 μM) for 24 hours (n=3, *p < 0.05 versus untreated group). 

GRP78; 

PubMed: 29383150     


Cells were treated with 50 μM erastin for various time(1-24 h). Whole-cell extracts were analyzed with immunoblotting assay.

27308510 31105999 28130223 29383150
Growth inhibition assay
Cell survival; 

PubMed: 29348676     


The A375 and G-361 human melanoma cells were treated with erastin (2.5-40 µM) or RSL3 (0.1-10 µM) with or without a cell death inhibitor (ferrostatin-1, 1 µM; ZVAD-FMK, 10 µM; necrosulfonamide, 0.5 µM) for 24 h. Cell death was assayed using a CCK-8 kit. Data shown represent mean ± SD from three independent experiments. ****p < 0.0001.

29348676
Immunofluorescence
HMGB1; 

PubMed: 31105999     


HL-60/NRAS (Q61L) cells were treated with erastin (5 μM) with or without Fer-1 (1 μM) pretreatment for 48 h, and then the nuclear/cytosolic HMGB1 expression was assayed by immunofluorescence(Green, HMGB1; blue, nucleus). 

31105999

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: BJ-TERT/LT/ST/RASV12细胞
  • Concentrations: 5 or 10 μg/mL
  • Incubation Time: 6-11小时
  • Method: BJ-TERT/LT/ST/RASV12细胞接种在100 mm平皿中,并使其生长过夜。细胞用erastin(5或10微克/毫升)处理6,8,或11小时。camptothecin处理(0.4微克/毫升)的对照被维持,在接种的时候处理20小时。处理后,细胞用胰蛋白酶/EDTA孵育并用含血清的新鲜培养基洗1次,然后用磷酸盐缓冲盐水洗涤两次。细胞同1×结合缓冲液重悬。100 μL重悬细胞在5μL的膜联蛋白V-FITC和碘化丙啶iodiode在黑暗中孵育15分钟。然后加入400 μl的1×结合缓冲液S并用流式细胞仪分析。采集数据,并使用CellQuest软件进行分析。只有不被碘化丙啶染色的活细胞使用FL1通道的膜联蛋白V-FITC染色分析。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 19 mg/mL (34.73 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG 300+5%Tween80+ddH2O
1.75mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 547.04
化学式

C30H31ClN4O4

CAS号 571203-78-6
储存条件 3年 -20°C 粉状
1个月 -80°C 溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
Tags: 购买Erastin | Erastin供应商 | 采购Erastin | Erastin价格 | Erastin生产 | 订购Erastin | Erastin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID